Additionally, sitravatinib inhibited expression of the M2 markers arginase 1, YM-1 and Fizz-1 upon stimulation with conditioned media from murine cancer cells – a source of TAM receptor ligands – and reduced immunosuppressive cell populations, such as MDSCs and M2 macrophages, in vivo [5]. Here, RETNLB is linked to cancer.